Skin Cancer in Skin of Color: What the Evidence Shows

Melanin absorbs ultraviolet radiation and contributes to lower rates of many UV-associated skin cancers in darker skin. Protection is incomplete. Melanoma, squamous cell carcinoma, basal cell carcinoma, and rarer skin cancers occur across the full range of skin tones, sometimes in sites or patterns that standard sun-focused messages do not emphasize.

Population averages are useful for planning, but they do not determine your diagnosis. A changing band beneath a nail, a wound that will not heal, or a growing spot on the sole deserves assessment regardless of race, ethnicity, or perceived baseline risk. The evidence also shows a disparity that requires careful explanation: several US groups with darker skin are more often diagnosed with melanoma at a later stage and have worse survival after diagnosis. Stage, subtype and site, access to dermatology and biopsy, recognition, and possibly tumor biology may all contribute. No single factor should be presented as the complete explanation.

Incidence and outcome answer different questions#

Incidence asks how often a cancer is diagnosed in a population. Prognosis asks what happens after it develops. Conflating them creates the mistaken idea that a less common disease cannot be serious in a particular group.

In the United States, melanoma incidence is much higher among non-Hispanic White populations than among Black, Asian, Hispanic, or Indigenous populations considered as broad categories. Those labels contain substantial variation and can obscure ancestry, skin phenotype, geography, socioeconomic conditions, and the way data are recorded. They should not be treated as biological diagnoses.

Lower incidence can coexist with later stage at diagnosis and lower melanoma-specific survival in some groups. A rare diagnosis may be considered later by patients and clinicians. Educational images may not represent darker skin well. Access to a clinician, referral, and biopsy can influence time to diagnosis. So can pathology expertise, insurance, and continuity of care. Acral and nail-unit melanomas also have distinct sites and biology. Analyses that adjust for stage often reduce outcome gaps, but do not always erase them. The responsible conclusion is multifactorial, not a claim that one behavior or one health-system feature explains every difference.

Why acral melanoma needs its own mental model#

Acral melanoma occurs on non-hair-bearing skin of the palms and soles or in the nail unit. It represents a larger share of melanomas diagnosed in people with darker skin because the more UV-associated forms are less frequent, not necessarily because acral melanoma is common overall in those populations.

The molecular pattern differs from typical sun-damaged cutaneous melanoma. Acral tumors often have fewer UV-signature mutations and different structural and driver alterations. Long-term sunlight is therefore not a satisfying explanation for a lesion on the sole. This distinction matters because a prevention message limited to sunscreen and sunlit sites can miss the places where suspicion is needed.

On a palm or sole, concern can arise from a new or evolving asymmetric patch, mixed color, irregular border, growth, bleeding, ulceration, or a lesion that differs from the person's other marks. Under a nail, a new dark longitudinal band or widening or irregularity warrants assessment. So does extension of pigment onto nearby skin, nail splitting, bleeding, or progressive nail destruction. Trauma and benign pigmentation are common alternatives, but a history of injury does not by itself exclude cancer.

Many people have benign, stable nail bands, sometimes in several nails. Clinicians interpret the full pattern, age, and onset. They interpret change, width, and color variation. They interpret number of nails, medications, skin findings, and examination with magnification. No single visual rule can replace that assessment.

How common skin cancers may appear#

Basal cell carcinoma often appears as a slowly growing bump, plaque, sore, or area that repeatedly crusts and bleeds. In darker skin it may be visibly pigmented, which can broaden the visual differential. It remains strongly linked to ultraviolet radiation and is often found on sunlit sites.

Squamous cell carcinoma can look like a scaly or thickened patch, firm bump, ulcer, or nonhealing wound. In darker-skinned populations, a greater proportion may arise in chronic scars, ulcers, or burns. It may arise in inflammatory lesions or areas with long-standing injury rather than on heavily sun-exposed skin. A wound that changes, becomes painful, bleeds, develops a raised edge, or fails to heal needs evaluation. This does not mean ordinary scars commonly turn into cancer. It identifies a setting in which persistent change deserves attention.

Color is only one signal. Redness can appear red-brown, violet, gray, or darker than surrounding skin. Inflammation may be easier to recognize through warmth, swelling, or scale. It may be easier to recognize through tenderness, texture, or comparison with nearby skin. Clinical teaching and image libraries need examples across skin tones because pattern recognition depends on what learners are shown.

Prevention without false reassurance or alarm#

Ultraviolet radiation is a preventable cause of skin cancer and photoaging. Shade, clothing, and hats are reasonable protective measures for all skin tones. So are sunglasses and broad-spectrum sunscreen, especially during substantial time in strong sunlight or when using photosensitizing medicines. Sun protection is not a guarantee, and it is not the main explanation for acral melanoma.

You should also know your own baseline. That can include the scalp, between toes, and soles. It can include palms, nails, and areas affected by chronic wounds or scars. A self-check is not a test with proven ability to reduce mortality, and intense checking can create anxiety and unnecessary procedures. Its practical purpose is to notice meaningful change and seek assessment, not to diagnose every mark.

The US Preventive Services Task Force has found insufficient evidence to determine the balance of benefits and harms of routine clinician visual screening in asymptomatic adolescents and adults at average risk. An I statement is not a recommendation against evaluating symptoms or a suspicious lesion. It also does not settle how people with prior skin cancer, strong familial risk, immunosuppression, or other elevated-risk features should be followed. See how to read a USPSTF skin cancer screening I statement for that distinction.

What an assessment and biopsy can establish#

A clinician begins with history and inspection, often using dermoscopy to see structures not visible to the unaided eye. The decision to monitor or biopsy depends on the lesion, site, and differential diagnosis. It depends on change, symptoms, and patient context. For a nail lesion, sampling technique matters because the source may be in the nail matrix or bed.

Pathology establishes whether sampled tissue is cancer and, if melanoma is present, measures features that guide staging and treatment. Sampling the wrong area or taking a superficial specimen can limit interpretation, which is why clinical-pathology communication matters. Images and history can help the pathologist understand the site and question.

If melanoma is diagnosed, thickness, ulceration, and lymph-node findings can affect management. So can anatomic stage and molecular features. Sentinel lymph-node biopsy is a staging procedure for selected melanomas, not a universal treatment and not a screening test. The evidence and tradeoffs are reviewed in sentinel lymph-node biopsy in melanoma.

Representation is an evidence-quality issue#

Algorithms, atlases, teaching sets, and public campaigns inherit the composition and labeling quality of their source images. A model trained mostly on lighter skin or on specialist photographs may fail when used on different tones, devices, settings, or disease distributions. Reporting aggregate accuracy can hide poor performance in an underrepresented group.

Validation should state skin-tone measurement, demographics, and lesion spectrum. It should state image source, reference standard, missing data, and subgroup uncertainty. Small subgroup counts produce wide confidence intervals. Race is not an adequate substitute for measured skin appearance, and a skin-tone scale is not a substitute for studying access and care pathways. Related limits in consumer tools are discussed in FDA-regulated AI skin-cancer detection evidence.

A practical threshold for seeking care#

Request an assessment for a new or changing spot that is asymmetric, irregular, or growing. Ask as well if it is differently colored, symptomatic, bleeding, or unlike your other lesions. The same applies to a persistent sore, a changing scar, pigment spreading around a nail, or unexplained progressive nail damage. Rapid change, significant bleeding, infection signs, or an enlarging mass can justify more urgent evaluation.

Photographs with a date and consistent lighting can document change while an appointment is arranged. They should not delay care when a lesion is concerning. A clinician may find a benign explanation, but that conclusion should follow appropriate assessment rather than an assumption that skin tone makes cancer impossible.

References#

1. National Cancer Institute: body location and acral melanoma genetics
2. American Academy of Dermatology: skin cancer in people of color
3. American Cancer Society: melanoma signs and symptoms
4. USPSTF recommendation on skin cancer screening
5. JAAD review of melanoma disparities in skin of color
6. Review of nonmelanoma skin cancer in skin of color

For your own health, talk with your clinician.*